The major goal of these studies is to develop markers predictive of which ductal carcinoma in situ (DCIS) cases will recur and/or become invasive to aid in the clinical management of mammographically-detected DCIS. To do this we will examine cases of pure DCIS and DCIS associated with invasive cancers for a number of molecular and immunohistochemical markers known to be abnormal in invasive cancers. Included among the markers to be evaluated are loss of heterozygosity (LOH) and gene amplification at various chromosomal loci, various immunohistochemical markers associated with invasion as well as markers associated with dysregulated proliferation and apoptosis. A second goal is to undertake preliminary studies to identify molecular markers in nonmalignant epithelium that might distinguish those cases likely to progress to cancer. These studies will concentrate on characterizing the morphologically nonmalignant mammary epithelium adjacent to malignancies, comparing this tissue to truly normal mammary epithelium and to other tissues of the patient (i.e., skin vs. mammary epithelium). If these studies are successful in identifying molecular aberrations in nonmalignant epithelium adjacent to malignancy, future studies beyond the scope of the proposal could evaluate marker efficacy for early diagnosis when used in combination with other diagnostic modalities such as needle aspirates and/or random nipple biopsies. Additionally, such markers mabe surrogates in chemoprevention trials for the currently used endpoint of malignancy which would allow trials to be performed with fewer patients and over shorter time periods.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058207-08S1
Application #
6352756
Study Section
Project Start
1999-08-01
Project End
2002-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
2000
Total Cost
$206,819
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Rice, Megan S; Tamimi, Rulla M; Bertrand, Kimberly A et al. (2018) Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 170:129-141
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Campbell, Michael J; Baehner, Frederick; O'Meara, Tess et al. (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17-28
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2017) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging 46:290-302
Olow, Aleksandra; Chen, Zhongzhong; Niedner, R Hannes et al. (2016) An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res 76:1733-45
Takai, Ken; Le, Annie; Weaver, Valerie M et al. (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7:82889-82901
Hu, Zhi; Mao, Jian-Hua; Curtis, Christina et al. (2016) Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res 18:70
Malkov, Serghei; Shepherd, John A; Scott, Christopher G et al. (2016) Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. Breast Cancer Res 18:122
Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol et al. (2016) Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget 7:14727-41

Showing the most recent 10 out of 339 publications